Hablemos de los efectos secundarios sexuales

Referencias
  1. Clayton AH, El Haddad S, Iluonakhamhe JP, Ponce Martinez C, Schuck AE. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert Opin Drug Saf. 2014 Oct;13(10):1361-74.
  2. Dale E, Bang-Andersen B, Sánchez C. Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochem Pharmacol. 2015 May 15;95(2):81-97.
  3. Druyts E, Eapen S, Wu P, Thorlund K. The risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysis. Syst Rev. 2014 Oct 13;3:116.
  4. Kingsberg SA, Clayton AH, Pfaus JG. The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder. CNS Drugs. 2015 Nov;29(11):915-33.
  5. Lyons DJ, Ammari R, Hellysaz A, Broberger C. Serotonin and Antidepressant SSRIs Inhibit Rat Neuroendocrine Dopamine Neurons: Parallel Actions in the Lactotrophic Axis. J Neurosci. 2016 Jul 13;36(28):7392-406.
  6. Montejo ÁL1, Arango C2, Bernardo M3, Carrasco JL4, Crespo-Facorro B5, Cruz JJ et al. Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia. [Article in English, Spanish]. Rev Psiquiatr Salud Ment. 2016 Jul-Sep;9(3):158-73.
  7. Montejo ÁL1, Arango C2, Bernardo M3, Carrasco JL4, Crespo-Facorro B5, Cruz JJ et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol. 2017 Apr;45:25-34.
  8. Park YW, Kim Y, Lee JH. Antipsychotic-induced sexual dysfunction and its management. World J Mens Health. 2012 Dec;30(3):153-9.
  9. Pfaus JG. Pathways of sexual desire. J Sex Med. 2009 Jun;6(6):1506-33.
  10. Stagkourakis S, Kim H, Lyons DJ, Broberger C. Dopamine Autoreceptor Regulation of a Hypothalamic Dopaminergic Network. Cell Rep. 2016 Apr 14. pii: S2211-1247(16)30333-3.
Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
Está usted abandonando Progress in Mind

Está usted abandonando

Progress in Mind España
Verificación de profesional sanitario obligatoria
Para obtener acceso, por favor proporcione la información necesaria para verificar que es un profesional de la salud
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
La información contenida en esta página web está dirigida exclusivamente al profesional sanitario.
Toda la información incluida en la Página Web está referida a productos del mercado español y, por tanto, dirigida a profesionales sanitarios legalmente facultados para prescribir o dispensar medicamentos con ejercicio profesional. La información técnica de los fármacos se facilita a título meramente informativo, siendo responsabilidad de los profesionales facultados prescribir medicamentos y decidir, en cada caso concreto, el tratamiento más adecuado a las necesidades del paciente.
Congress
Register for access to Progress in Mind in your country